- Home
- SSY vs LYRA Comparison
SSY vs LYRA Comparison
Compare SSY & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSY
- LYRA
- Stock Information
- Founded
- SSY 1959
- LYRA 2005
- Country
- SSY United States
- LYRA United States
- Employees
- SSY N/A
- LYRA N/A
- Industry
- SSY Hospital/Nursing Management
- LYRA Medical/Dental Instruments
- Sector
- SSY Health Care
- LYRA Health Care
- Exchange
- SSY Nasdaq
- LYRA Nasdaq
- Market Cap
- SSY 6.3M
- LYRA 6.1M
- IPO Year
- SSY N/A
- LYRA 2020
- Fundamental
- Price
- SSY $0.88
- LYRA $0.10
- Analyst Decision
- SSY
- LYRA Hold
- Analyst Count
- SSY 0
- LYRA 4
- Target Price
- SSY N/A
- LYRA $1.25
- AVG Volume (30 Days)
- SSY 13.1K
- LYRA 1.7M
- Earning Date
- SSY 05-14-2025
- LYRA 04-29-2025
- Dividend Yield
- SSY N/A
- LYRA N/A
- EPS Growth
- SSY N/A
- LYRA N/A
- EPS
- SSY 0.14
- LYRA N/A
- Revenue
- SSY $31,233,000.00
- LYRA $1,534,000.00
- Revenue This Year
- SSY N/A
- LYRA N/A
- Revenue Next Year
- SSY N/A
- LYRA $237.15
- P/E Ratio
- SSY $6.05
- LYRA N/A
- Revenue Growth
- SSY N/A
- LYRA N/A
- 52 Week Low
- SSY $0.53
- LYRA $0.08
- 52 Week High
- SSY $1.91
- LYRA $5.65
- Technical
- Relative Strength Index (RSI)
- SSY 44.82
- LYRA 38.11
- Support Level
- SSY $0.85
- LYRA $0.08
- Resistance Level
- SSY $0.98
- LYRA $0.10
- Average True Range (ATR)
- SSY 0.10
- LYRA 0.02
- MACD
- SSY -0.00
- LYRA 0.00
- Stochastic Oscillator
- SSY 61.54
- LYRA 41.71
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.